Wen-Kai Weng
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Wen-Kai Weng as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00899847 · Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATGStanford University · completed · Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma · principal investigator
- Ph2NCT00896493 · Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell LymphomaStanford University · completed · Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous · principal investigator
- Ph2NCT00482053 · Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTStanford University · terminated · Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL) · principal investigator
- Ph2NCT00481832 · Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's LymphomaStanford University · terminated · Lymphoma, Non-Hodgkin · principal investigator
- N/ANCT00398372 · Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody TreatmentStanford University · completed · Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma · principal investigator
- Ph2NCT00186394 · High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's LymphomaStanford University · completed · Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin · principal investigator
- Ph2NCT00185614 · Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple MyelomaWen-Kai Weng · completed · Blood Cancer, Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Mechanism of Antibody Therapy in Human B Cell LymphomaK08CA111827 · NCI · STANFORD UNIVERSITY · fiscal years 2005 to 2007 · $138,105 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:52 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- 550 citationsRCR 27.4
- Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.Circulation · 2007343 citationsRCR 9.0
- Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.N Engl J Med · 2021251 citationsRCR 17.0
- Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.Hepatology · 2017243 citationsRCR 9.3
- 229 citationsRCR 7.8
- Characterizations of particle size distribution of the droplets exhaled by sneeze.J R Soc Interface · 2013192 citationsRCR 6.8
- 137 citationsRCR 6.8
- 131 citationsRCR 3.0
- The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.Diabetes Obes Metab · 2007103 citationsRCR 3.0
- 99 citationsRCR 21.9